SFARI consultant-in-residence Gaspar Taroncher-Oldenburg discusses his work and collaboration with the Simons Foundation Flatiron Institute to study the microbiome and its potential implications for ASD research.
J. Elliott Robinson talks about his lab’s work on the neural circuits involved in neurofibromatosis type 1 and developing gene therapy treatments for the condition, and how the SFARI BTI and SEED awards have aided these efforts.
SFARI Investigator Aakanksha Singhvi discusses her lab’s work and how the Bridge to Independence Award helped in her transition to working as an assistant professor.
SFARI Investigator Kevin Eggan discusses his research on induced pluripotent stem (iPS) cells and his collaboration with SFARI to provide a detailed characterization of iPS cell lines from Simons Searchlight participants.
Peter Kind and Loren Frank discuss their work using SFARI’s genetic rat models and their views on how these models will aid autism research.
SFARI Investigator Karen Parker discusses her preclinical and clinical research on the neuropeptides arginine vasopressin and oxytocin as potential biomarkers and treatment strategies for autism spectrum disorder.
SFARI Investigator Dan Feldman discusses the E-I ratio hypothesis in autism and his lab’s recent studies that aimed to test it.
SFARI Investigator Seth Shipman discusses his lab’s research on the molecular and cellular mechanisms shaping brain development and how the Bridge to Independence Award is helping him launch his independent research career.
Paul Wang, Deputy Director of Clinical Research Associates, L.L.C. (CRA), discusses the research that CRA supports, including human and animal studies using arbaclofen, a potential drug treatment for autism.
SFARI Investigator David Ginty talks about the links between deficits in the sense of touch, tactile hypersensitivity, and alterations in social behaviors in autism.